Keyphrases
Ligand-receptor Binding
100%
Hyperoxia-induced Lung Injury
100%
AT2R
100%
Newborn Rats
100%
Heart Injury
100%
PD123319
100%
Right Ventricular Hypertrophy
87%
Arterial Hypertension
50%
Bronchopulmonary Dysplasia
50%
Beneficial Effects
37%
Hyperoxia
37%
Late Treatment
25%
Early Treatment
25%
Treatment Model
25%
Cardiopulmonary Injury
25%
Therapeutic Potential
12%
High Concentration
12%
Neutrophils
12%
Macrophages
12%
Inflammatory Cells
12%
Medial Wall
12%
Recovery Period
12%
Pulmonary Inflammation
12%
Fibrin Deposition
12%
Differential mRNA Expression
12%
Vascular Leakage
12%
Vascular Development
12%
Continuous Exposure
12%
Wall Thickness
12%
Cardiopulmonary Effects
12%
Alveolar Development
12%
Lung Inflammation
12%
Extravascular
12%
Room Air
12%
Collagen III
12%
Rat Pups
12%
Pulmonary Fibrosis
12%
Septal Thickness
12%
Neonatal Period
12%
Lung Histology
12%
Twice a Day
12%
Days of Treatment
12%
Heart Histopathology
12%
Medicine and Dentistry
Low Drug Dose
100%
Neonatal Infant
100%
Hyperoxia-Induced Lung Injury
100%
Angiotensin II Receptor Type 2
100%
1 (4 Dimethylamino 3 Methylbenzyl) 5 Diphenylacetyl 4,5,6,7 Tetrahydro 1h imidazo[4,5 C]pyridine 6 Carboxylic Acid
100%
Heart Injury
100%
Right Ventricular Hypertrophy
87%
Hypertension
50%
Lung Dysplasia
50%
Hyperoxia
37%
Pneumonia
25%
Lung
12%
Inflammatory Cell
12%
Histopathology
12%
Arteriole
12%
Fibrin Deposition
12%
Macrophage
12%
Pulmonary Fibrosis
12%
Newborn Period
12%
Messenger RNA
12%
Neutrophil
12%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Angiotensin II
100%
Hyperoxia-Induced Lung Injury
100%
1 (4 Dimethylamino 3 Methylbenzyl) 5 Diphenylacetyl 4,5,6,7 Tetrahydro 1h imidazo[4,5 C]pyridine 6 Carboxylic Acid
100%
Heart Injury
100%
Heart Right Ventricle Hypertrophy
87%
Lung Dysplasia
50%
Hypertension
50%
Pneumonia
25%
Lung Fibrosis
12%
Messenger RNA
12%